Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

PAI-1 and atherothrombosis.

D E Vaughan1

  • 1Division of Cardiovascular Medicine, Vanderbilt University Medical Center, Nashville, TN 37232-6300, USA. doug.vaughan@vanderbilt.edu

Journal of Thrombosis and Haemostasis : JTH
|August 17, 2005
PubMed
Summary

Plasminogen activator inhibitor-1 (PAI-1) is linked to higher risks of cardiovascular events. Targeting PAI-1 may help reduce atherothrombotic events and slow vascular disease progression.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

New directions in thrombolytic therapy Molecular mutants and biochemical conjugates.

Trends in cardiovascular medicine·2011
Same author

The Renin-Angiotensin and fibrinolytic systems co-conspirators in the pathogenesis of ischemic cardiovascular disease.

Trends in cardiovascular medicine·2011
Same author

Male-female differences in the genetic regulation of t-PA and PAI-1 levels in a Ghanaian population.

Human genetics·2008
Same author

Response of fractional synthesis rate (FSR) of fibrinogen, concentration of D-dimer and fibrinolytic balance to physical activity-based intervention in obese children.

Journal of thrombosis and haemostasis : JTH·2008
Same author

Transgenic over-expression of plasminogen activator inhibitor-1 results in age-dependent and gender-specific increases in bone strength and mineralization.

Bone·2007
Same author

The bradykinin type 2 receptor BE1 polymorphism and ethnicity influence systolic blood pressure and vascular resistance.

Clinical pharmacology and therapeutics·2007

Area of Science:

  • Cardiovascular Biology
  • Thrombosis Research

Background:

  • Plasminogen activator inhibitor-1 (PAI-1) is the primary inhibitor of tissue-type plasminogen activator in plasma.
  • Elevated PAI-1 levels are observed in conditions linked to increased ischemic cardiovascular event risk.

Purpose of the Study:

  • To investigate the role of PAI-1 beyond being a passive factor in ischemic heart disease.
  • To explore the potential of PAI-1 antagonists in testing the hypothesis that excess PAI-1 drives atherothrombosis and atherosclerosis.

Main Methods:

  • Review of recent biological insights into PAI-1.
  • Conceptual framework for testing PAI-1 antagonist efficacy.

Main Results:

  • PAI-1 is implicated in increasing atherothrombotic event risk.
  • PAI-1 may contribute to the progression of vascular disease.

Conclusions:

  • PAI-1 is an active participant in the pathogenesis of vascular disease.
  • Development of PAI-1 antagonists is crucial for validating its role in thrombosis and atherosclerosis.

Related Experiment Videos